论文部分内容阅读
Avery 和 Mead(1959)提出:“呼吸窘迫综合征(RDS)与某种物质缺乏或延迟出现有关,在正常人当肺容量减少时,这种物质能使肺泡内面获得较低的表面张力”。此后有人企图通过替代此物质达到改善疾病的目的,并将其定名为表面活性剂。
Avery and Mead (1959) argue that “respiratory distress syndrome (RDS) is associated with a lack of or delay in the appearance of a substance that causes a lower surface tension in the inner alveolar surface when normal lung capacity is reduced.” Since then there has been an attempt to improve the disease by substituting this substance for the purpose of naming it a surfactant.